{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:38:26Z","timestamp":1761766706598},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Da Volterra"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Clostridioides difficile infection (CDI) remains a high burden worldwide. DAV131A, a novel adsorbent, reduces residual gut antimicrobial levels, reducing CDI risk in animal models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We used a validated human gut model to investigate the efficacy of DAV131A in preventing moxifloxacin-induced CDI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>C. difficile (CD) spores were inoculated into two models populated with pooled human faeces. Moxifloxacin was instilled (43\u2009mg\/L, once daily, 7\u2009days) alongside DAV131A (5\u2009g in 18\u2009mL PBS, three times daily, 14\u2009days, Model A), or PBS (18\u2009mL, three times daily, 14\u2009days, Model B). Selected gut microbiota populations, CD total counts, spore counts, cytotoxin titre and antimicrobial concentrations (HPLC) were monitored daily. We monitored for reduced susceptibility of CD to moxifloxacin. Growth of CD in faecal filtrate and medium in the presence\/absence of DAV131A, or in medium pre-treated with DAV131A, was also investigated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>DAV131A instillation reduced active moxifloxacin levels to below the limit of detection (50\u2009ng\/mL), and prevented microbiota disruption, excepting Bacteroides fragilis group populations, which declined by \u223c3\u2005log10\u2005cfu\/mL. DAV131A delayed onset of simulated CDI by \u223c2\u2009weeks, but did not prevent CD germination and toxin production. DAV131A prevented emergence of reduced susceptibility of CD to moxifloxacin. In batch culture, DAV131A had minor effects on CD vegetative growth, but significantly reduced toxin\/spores (P\u2009&amp;lt;\u20090.005).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>DAV131A reduced moxifloxacin-induced microbiota disruption and emergence of antibiotic-resistant CD. Delayed onset of CD germination and toxin production indicates further investigations are warranted to understand the clinical benefits of DAV131A in CDI prevention.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa062","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T12:09:19Z","timestamp":1580904559000},"page":"1458-1465","source":"Crossref","is-referenced-by-count":3,"title":["Investigation of the effect of the adsorbent DAV131A on the propensity of moxifloxacin to induce simulated Clostridioides (Clostridium) difficile infection (CDI) in an in vitro human gut model"],"prefix":"10.1093","volume":"75","author":[{"given":"C H","family":"Chilton","sequence":"first","affiliation":[{"name":"Healthcare Associated Infections Research Group, Leeds Institute for Medical Research, University of Leeds, Old Medical School, Leeds General Infirmary, Leeds LS1 3EX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G S","family":"Crowther","sequence":"additional","affiliation":[{"name":"Division of Pharmacy and Optometry, University of Manchester, Manchester M13 9PT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Miossec","sequence":"additional","affiliation":[{"name":"Da Volterra, Le Dorian (b\u00e2t B1), 172 rue de Charonne, 75011 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"de Gunzburg","sequence":"additional","affiliation":[{"name":"Da Volterra, Le Dorian (b\u00e2t B1), 172 rue de Charonne, 75011 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Andremont","sequence":"additional","affiliation":[{"name":"IAME INSERM, UMR 1137, University of Paris, 75018 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M H","family":"Wilcox","sequence":"additional","affiliation":[{"name":"Healthcare Associated Infections Research Group, Leeds Institute for Medical Research, University of Leeds, Old Medical School, Leeds General Infirmary, Leeds LS1 3EX, UK"},{"name":"Microbiology, Leeds Teaching Hospitals NHS Trust, Old Medical School, Leeds General Infirmary, Leeds LS1 3EX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"key":"2020071623501929100_dkaa062-B1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.anaerobe.2016.06.008","article-title":"Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O\u2019Toole 1935) Prevot 1938","volume":"40","author":"Lawson","year":"2016","journal-title":"Anaerobe"},{"key":"2020071623501929100_dkaa062-B2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nrgastro.2016.25","article-title":"Clostridium difficile infection: epidemiology, diagnosis and understanding transmission","volume":"13","author":"Martin","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2020071623501929100_dkaa062-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhin.2012.02.004","article-title":"Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection","volume":"81","author":"Wiegand","year":"2012","journal-title":"J Hosp Infect"},{"key":"2020071623501929100_dkaa062-B4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.medmal.2017.10.010","article-title":"Economic burden and cost-effective management of Clostridium difficile infections","volume":"48","author":"Heimann","year":"2018","journal-title":"Med Mal Infect"},{"key":"2020071623501929100_dkaa062-B5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jinf.2009.03.010","article-title":"Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes","volume":"58","author":"Johnson","year":"2009","journal-title":"J Infect"},{"key":"2020071623501929100_dkaa062-B6","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1056\/NEJMoa1408913","article-title":"Burden of Clostridium difficile infection in the United States","volume":"372","author":"Lessa","year":"2015","journal-title":"N Engl J Med"},{"key":"2020071623501929100_dkaa062-B7","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1046\/j.1365-2036.1998.00428.x","article-title":"Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam","volume":"12","author":"Settle","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"2020071623501929100_dkaa062-B8","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/jac\/dkt477","article-title":"Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis","volume":"69","author":"Slimings","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2020071623501929100_dkaa062-B9","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.02176-12","article-title":"Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection","volume":"57","author":"Brown","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071623501929100_dkaa062-B10","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/496986","article-title":"Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec","volume":"41","author":"Pepin","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020071623501929100_dkaa062-B11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1473-3099(16)30514-X","article-title":"Effects of control interventions on Clostridium difficile infection in England: an observational study","volume":"17","author":"Dingle","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2020071623501929100_dkaa062-B12","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3390\/genes6041347","article-title":"Disruption of the gut microbiome: Clostridium difficile infection and the threat of antibiotic resistance","volume":"6","author":"Johanesen","year":"2015","journal-title":"Genes"},{"key":"2020071623501929100_dkaa062-B13","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/infdis\/jix604","article-title":"Protection of the human gut microbiome from antibiotics","volume":"217","author":"de Gunzburg","year":"2018","journal-title":"J Infect Dis"},{"key":"2020071623501929100_dkaa062-B14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00925-18","article-title":"Antibiotic-induced dysbiosis predicts mortality in an animal model of Clostridium difficile infection","volume":"62","author":"Burdet","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071623501929100_dkaa062-B15","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00543-17","article-title":"Protection of hamsters from mortality by reducing fecal moxifloxacin concentration with DAV131A in a model of moxifloxacin-induced Clostridium difficile colitis","volume":"61","author":"Burdet","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071623501929100_dkaa062-B16","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1128\/AAC.00306-08","article-title":"Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model","volume":"53","author":"Saxton","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071623501929100_dkaa062-B17","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/jac\/dkl364","article-title":"Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model","volume":"58","author":"Baines","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2020071623501929100_dkaa062-B18","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/jac\/dki120","article-title":"Effects of piperacillin\/tazobactam on Clostridium difficile growth and toxin production in a human gut model","volume":"55","author":"Baines","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2020071623501929100_dkaa062-B19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/jac\/dkg267","article-title":"Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut","volume":"52","author":"Freeman","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2020071623501929100_dkaa062-B20","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/jac\/dkr584","article-title":"Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model","volume":"67","author":"Chilton","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2020071623501929100_dkaa062-B21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/00365540050164272","article-title":"Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microbiota","volume":"32","author":"Edlund","year":"2000","journal-title":"Scand J Infect Dis"},{"key":"2020071623501929100_dkaa062-B22","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1128\/IAI.71.4.1784-1793.2003","article-title":"Expression of Clostridium difficile toxins A and B and their sigma factor TcdD is controlled by temperature","volume":"71","author":"Karlsson","year":"2003","journal-title":"Infect Immun"},{"key":"2020071623501929100_dkaa062-B23","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1099\/13500872-145-7-1683","article-title":"Suppression of toxin production in Clostridium difficile VPI 10463 by amino acids","volume":"145","author":"Karlsson","year":"1999","journal-title":"Microbiology"},{"key":"2020071623501929100_dkaa062-B24","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1099\/jmm.0.056218-0","article-title":"Effects of ciprofloxacin on the expression and production of exotoxins by Clostridium difficile","volume":"62","author":"Aldape","year":"2013","journal-title":"J Med Microbiol"},{"key":"2020071623501929100_dkaa062-B25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/jac\/dku325","article-title":"Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile","volume":"70","author":"Aldape","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020071623501929100_dkaa062-B26","doi-asserted-by":"crossref","first-page":"5881","DOI":"10.1128\/IAI.68.10.5881-5888.2000","article-title":"Toxins, butyric acid, and other short-chain fatty acids are coordinately expressed and down-regulated by cysteine in Clostridium difficile","volume":"68","author":"Karlsson","year":"2000","journal-title":"Infect Immun"},{"key":"2020071623501929100_dkaa062-B27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2958.1998.00663.x","article-title":"Regulated transcription of Clostridium difficile toxin genes","volume":"27","author":"Dupuy","year":"1998","journal-title":"Mol Microbiol"},{"key":"2020071623501929100_dkaa062-B28","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1128\/JB.00882-09","article-title":"Characterization of the sporulation initiation pathway of Clostridium difficile and its role in toxin production","volume":"191","author":"Underwood","year":"2009","journal-title":"J Bacteriol"},{"key":"2020071623501929100_dkaa062-B29","doi-asserted-by":"crossref","first-page":"e48608.","DOI":"10.1371\/journal.pone.0048608","article-title":"C. difficile 630\u0394erm Spo0A regulates sporulation, but does not contribute to toxin production, by direct high-affinity binding to target DNA","volume":"7","author":"Rosenbusch","year":"2012","journal-title":"PLoS One"},{"key":"2020071623501929100_dkaa062-B30","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/IAI.00147-12","article-title":"The Clostridium difficile spo0A gene is a persistence and transmission factor","volume":"80","author":"Deakin","year":"2012","journal-title":"Infect Immun"},{"key":"2020071623501929100_dkaa062-B31","doi-asserted-by":"crossref","first-page":"e79666.","DOI":"10.1371\/journal.pone.0079666","article-title":"Spo0A differentially regulates toxin production in evolutionarily diverse strains of Clostridium difficile","volume":"8","author":"Mackin","year":"2013","journal-title":"PLoS One"},{"key":"2020071623501929100_dkaa062-B32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nature13828","article-title":"Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile","volume":"517","author":"Buffie","year":"2015","journal-title":"Nature"},{"key":"2020071623501929100_dkaa062-B33","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1128\/AAC.01820-15","article-title":"Fluoroquinolone and macrolide exposure predict Clostridium difficile infection with the highly fluoroquinolone- and macrolide-resistant epidemic C. difficile strain BI\/NAP1\/027","volume":"60","author":"Wieczorkiewicz","year":"2016","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/6\/1458\/33213819\/dkaa062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/6\/1458\/33213819\/dkaa062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T13:37:02Z","timestamp":1594993022000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/6\/1458\/5757987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,25]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,2,25]]},"published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa062","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6]]},"published":{"date-parts":[[2020,2,25]]}}}